..., including Oncotype DX, are expensive and not covered by insurance in some countries Methods: In this study, we retrospectively analyzed a series of 155 patients with estrogen receptor-positive primary BC for whom an Oncotype DX assay was performed between January 2016 and August 2021. The patients’ modified...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Estrogen receptor Estrogen dependence Metastatic breast cancer Ligand-binding domain mutations Cancer is the number one killer of Americans, with the World Health...

... patients who were treated in our institute for estrogen receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer between April 2005 and March 2012 and whose tumors were sent for Oncotype-DX analysis were included. Medical records were retrospectively reviewed. Data regarding...

...Tal Grenader; Rinat Yerushalmi; Margarita Tokar; Georgeta Fried; Bella Kaufman; Tamar Peretz; David B. Geffen Objective: The 21-gene recurrence score (RS) assay has been widely adopted for use in early estrogen receptor (ER)-positive breast cancer to assess the risk for distant recurrence...

..., Gray R: Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-2746. 5. Anderson WF, Chen BE, Jatoi I, Rosenberg PS: Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treat...

... relationship with estrogen receptor (ER) and progesterone receptor (PR) in endometrioid endometrial cancer. Methods: FASN expression in endometrioid endometrial cancer was assessed by immunohistochemistry using 108 paraffin-embedded tissue specimens and clinical data collected from a retrospective chart review...

... of rapamycin mTOR Estrogen receptor Human epidermal growth factor receptor 2 Breast cancer, accounting for 28% of all cancers affecting women in the United States, is the most common cancer among women, with over 207,000 new cases reported in 2010 [ 1 ]. Even though death rates have fallen steadily...

...Jessica E. Pritchard; Patrick M. Dillon; Mark R. Conaway; Corinne M. Silva; Sarah J. Parsons Objective: Estrogen treatment limits the cytotoxic effects of chemotherapy in estrogen receptor-positive (ER+) breast cancer cell lines, suggesting that estrogen pathway signaling may confer...

... retrospective case-control study was to evaluate whether CXCR4 expression is more effective than conventional markers (estrogen receptor and HER-2) in predicting bone relapse in breast cancer. Methods: CXCR4 expression was evaluated by immunohistochemical staining in paraffin-embedded tissue sections of primary...

.... Androgen Estrogen Androgen receptor Estrogen receptor Hepatocellular carcinoma Hepatitis B virus The incidence of hepatocellular carcinoma (HCC) ranks fifth for cancers worldwide and causes about half a million deaths every year [ 1 ]. HCC is usually one of the grave outcomes from chronic...

...Vincenzo Emanuele Chiuri; Vito Lorusso Estrogen receptor expression in breast cancer cells represents an important predictive and prognostic factor. The estrogen receptor is a target for endocrine therapy, which avoids chemotherapy especially in highly hormone-sensitive early breast cancer...

...Grazia Arpino; Carmine De Angelis; Mario Giuliano; Antonio Giordano; Claudette Falato; Michele De Laurentiis; Sabino De Placido Endocrine therapy, the first targeted therapy in oncology, is the most successful systemic therapy in the management of estrogen receptor (ER)-positive breast cancer...

... patients in Japan. We were interested in whether OK-432 augments estrogen receptor (ER) levels in breast cancer. To investigate the effect of the BRMs on cellular growth and the characteristics of ER and progesterone receptors (PgR) in the human breast cancer cell line MCF-7, we used OK-432, Krestin (PSK...

... to in the content or advertisements. Enzyme immunoassay Estrogen receptor Progesterone receptor Radioligand assay Original Paper Oncology 1994;51:435-439 F. Jarque A. Lluch E. Vizcarra M. Muñoz V. Alberola J. Garciá-Conde Servicio de Hematología y Oncología Médica, Hospital Clínico Universitario...

...Shuji Takahashi; Eimei Narimatsu; Hiroko Asanuma; Minoru Okazaki; Akira Okazaki; Koichi Hirata; Michio Mori; Takayuki Chiba; Noriyuki Sato; Kokichi Kikuchi The authors immunohistochemically studied the expression of the estrogen receptor (ER), 27-kD heat shock protein (HSP27) and pS2 in 118...

... from 93 females and 37 males, and 144 carcinomas from 99 females and 45 males were used for the present immunohistochemical assessment of estrogen receptor (ER) expression. Thirty-three cases of follicular carcinoma, 115 cases of papillary carcinoma and 6 cases of anaplastic carcinoma were included...

...Noboru Konishi; Shingo Nakaoka; Yoshio Hiasa; Yoshiteru Kitahori; Masato Ohshima; Shoji Samma; Eigoro Okajima The levels of estrogen receptors in human benign prostatic hypertrophy and in various pathological classifications of prostate carcinoma were assessed using immunohistochemical methods. All...

...Yuichi lino; Masaru Izuo; Hiroo Takikawa Effects of trilostane (TLS) on 7,12-dimethylbenz[α]anthracene (DMBA)-induced mammary cancers and body weight of rats were examined in relation to estrogen receptors (ER) in 103 female Sprague-Dawley rats with DMBA-induced cancers. The inhibitory effects...

...C. Manegold; K. Klinga; B. Krempien; G. Schettler The purpose of our study was to clarify whether the amount of tissue extracted by means of iliac crest needle biopsy (ICNB) would suffice for a quantitative determination of estrogen receptors (ER) in bone metastases, and to see if the method...

... Miyauchi, Hiroki Koyama Department of Surgery. Center for Adult Diseases, Osaka. Japan Key Words. lct,25-(OH)2D3 Estrogen receptor Mammary tumor Abstract. The influence of la,25-dihydroxyvitamin D3 (l,25-(OH)2D3) on the development and steroid hormone receptor contents of 7,12-dimethylbenzanthracene...